Serafin Morales Murillo
Grau: Doctor/a
973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat
ResearcherID: http://www.researcherid.com/rid/L-7216-2019
Publicacions
-
Freyer, G; Martinez-Jañez, N; Kukielka-Budny, B; Ulanska, M; Bourgeois, H; Muñoz, M; Morales, S; Calero, JB; Cortesi, L; Pintér, T; Palácová, M; Cherciu, N; Petru, E; Ettl, J; de Almeida, C; Villanova, G; Raymond, R; Minh, CTT; Rodrigues, A; Cazzaniga, ME
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study
BREAST 74 103681-103681. .
-
Martinez-Jañez, N; Ezquerra, MB; Sanchez, LMM; Carrasco, FH; Torres, AA; Morales, S; Ortega, PT; Gil, VLO; Sampedro, T; Conejero, RA; Calvo-Martinez, L; Galve-Calvo, E; López, R; de la Pena, FA; Lopez-Tarruella, S; de Araguiz, BAHF; Ruiz, LB; Cardenas, TM; Chacon, JI; Antón, FM
First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN
BREAST CANCER RESEARCH AND TREATMENT 206 57-65. .
-
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
CLINICAL CANCER RESEARCH 30 334-343. .
-
Pont, M; Marques, M; Sorolla, MA; Parisi, E; Urdanibia, I; Morales, S; Salud, A; Sorolla, A
Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research
Cancers 15 -. .
-
Schmid P; Cortes J; Joaquim A; Jañez NM; Morales S; Díaz-Redondo T; Blau S; Neven P; Lemieux J; García-Sáenz JÁ; Hart L; Biyukov T; Baktash N; Massey D; Burris HA 3rd; Rugo HS
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
BREAST CANCER RESEARCH 25 67-67. .
-
Martín M; Zielinski C; Ruiz-Borrego M; Carrasco E; Ciruelos EM; Muñoz M; Bermejo B; Margelí M; Csöszi T; Antón A; Turner N; Casas MI; Morales S; Alba E; Calvo L; de la Haba-Rodríguez J; Ramos M; Murillo L; Santaballa A; Alonso-Romero JL; Sánchez-Rovira P; Corsaro M; Huang X; Thallinger C; Kahan Z; Gil-Gil M
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
EUROPEAN JOURNAL OF CANCER 168 12-24. .
-
Marques, M; Sorolla, MA; Urdanibia, I; Parisi, E; Hidalgo, I; Morales, S; Salud, A; Sorolla, A
Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
Cancers 14 -. .
-
Ocaña A; Chacon, JI; Calvo, L; Anton, A; Mansutti, M; Albanell, J; Martinez, MT; Lahuerta, A; Bisagni, G; Bermejo, B; Semiglazov, V; Thill, M; Chan, ARE; Morales, S; Herranz, J; Tusquets, I; Chiesa, M; Caballero, R; Valagussa, P; Bianchini, G; Alba, E; Gianni, L
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Frontiers in oncology 11 827625-827625. .
-
Yao, HM; Jones, SR; Morales, S; Moosavi, S; Zhang, J; Freyman, A; Ottery, FD
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 88 1033-1048. .
-
Kahan, Z; Gil-Gil, M; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Casas, M; Csoszi, T; Murillo, L; Morales, S; Calvo, L; Lang, I; Alba, E; de la Haba-Rodriguez, J; Ramos, M; Lopez, IA; Gal-Yam, E; Garcia-Palomo, A; Alvarez, E; Gonzalez-Santiago, S; Rodriguez, CA; Servitja, S; Corsaro, M; Rodrigalvarez, G; Zielinski, C; Martin, M
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
EUROPEAN JOURNAL OF CANCER 156 70-82. .
-
Gil-Gil, MJ; Bellet, M; Bergamino, M; Morales, S; Barnadas, A; Manso, L; Saura, C; Fernandez-Ortega, A; Garcia-Martinez, E; Martinez-Janez, N; Mele, M; Villagrasa, P; Celiz, P; Martin, XP; Ciruelos, E; Pernas, S
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
Frontiers in oncology 11 -. .
-
Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Turner, N; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Kahan, Z; Csoszi, T; Casas, MI; Murillo, L; Morales, S; Alba, E; Gal-Yam, E; Guerrero-Zotano, A; Calvo, L; de la Haba-Rodriguez, J; Ramos, M; Alvarez, I; Garcia-Palomo, A; Bartlett, CH; Koehler, M; Caballero, R; Corsaro, M; Huang, X; Garcia-Saenz, JA; Chacon, JI; Swift, C; Thallinger, C; Gil-Gil, M
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
ANNALS OF ONCOLOGY 32 488-499. .
Projectes
- Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
- SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
- Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante
